Skip to main content
Top

09-09-2024 | Idiopathic Pulmonary Fibrosis | News

ERS 2024

Bexotegrast shows ‘potential for disease modification’ in IPF

Author: Dr. Shreeya Nanda

medwireNews: Early results from a phase 2a trial show that 12 weeks of treatment with the novel agent bexotegrast reduced type 1 collagen deposition in patients with idiopathic pulmonary fibrosis (IPF).

Related topics

SPONSORED

Targeting COPD with type 2 inflammation: emerging biologic landscape

  • Live
  • Webinar | 03-12-2024 | 19:00 (CET)

LIVE: Tuesday, 3 December 2024, 19:00-20:30 (CET)

Join us for an insightful session tailored for pulmonologists and healthcare professionals eager to enhance their understanding of COPD and the latest advances in biologic therapies. 

Sponsored by:
  • Sanofi
Developed by: Springer Healthcare
Reserve your place

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases